Nuestros recursos

Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.

ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to be conducted where the majority of patients recover from illness—in their homes. When the trial was launched in 2021, its unique combination of home health visits, electronic patient-reported outcomes (ePRO), and remote monitoring devices was pioneering—COVID-19 studies were typically conducted inside hospitals.

The increased adoption of digital health technologies will be an enduring positive legacy of the pandemic. Telehealth immediately springs to mind, but the increased and more sophisticated use of remote patient monitoring is another encouraging evolution, with the potential to radically improve the clinical trial experience. Here are five key things to keep in mind when planning for RPM in your next DCT.

Low Risk, High Reward: Harnessing A Hybrid Approach to Pharmaceutical Clinical Trials

Digital transformation is reshaping nearly every industry, and clinical trials are no exception. As technology plays a bigger role in healthcare, patients are demanding more access to medical research. It’s not just patients who are asking for more: Medical professionals, researchers, and pharmaceutical companies all want to improve quality, efficiency, and access to clinical trials.